Wilmington, DE…77% reduced risk of developing symptomatic COVID-19. First long-acting antibody combination to prevent COVID-19. Positive high-level results from the PROVENT Phase III pre-exposure prophylaxis trial showed AstraZeneca’s AZD7442 achieved a statistically significant reduction in the incidence of symptomatic COVID-19, the trial’s primary endpoint. AZD7442, a combination of two long-acting antibodies (LAAB), reduced the risk of developing symptomatic COVID-19 by 77% (95% confidence interval (CI): 46, 90), compared to placebo. The trial accrued 25 cases of symptomatic COVID-19 at the primary analysis. There were no cases of severe COVID-19 or COVID-19-related deaths in those tre
Hence then, the article about astrazeneca therapeutic trials show 77 reduced risk of symptomatic covid was published today ( ) and is available onThepintree.net ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( AstraZeneca Therapeutic Trials Show 77% Reduced Risk of Symptomatic Covid )